| 磷酸二酯酶4抑制剂治疗银屑病的研究进展 |
| |
| 引用本文： | 张婷,张敏,丽丽,闫静茹,陈佩珊,郝玉琴.磷酸二酯酶4抑制剂治疗银屑病的研究进展[J].现代药物与临床,2022,37(4):912-916. |
| |
| 作者姓名： | 张婷 张敏 丽丽 闫静茹 陈佩珊 郝玉琴 |
| |
| 作者单位： | 内蒙古医科大学,内蒙古 呼和浩特 010000;内蒙古包钢医院(内蒙古医科大学第三附属医院)皮肤性病科,内蒙古 包头 014010,内蒙古包钢医院(内蒙古医科大学第三附属医院)皮肤性病科,内蒙古 包头 014010,北京大学第三医院 皮肤科,北京 100191 |
| |
| 摘 要： | 银屑病是一种遗传和环境共同作用诱发的、免疫介导的慢性炎症性皮肤病.环磷酸腺苷(cAMP)/蛋白激酶A(PKA)通路与银屑病的发病机制密切相关,而磷酸二酯酶4是可以专一水解cAMP的酶,因此磷酸二酯酶4成为银屑病治疗的期望小分子靶点.磷酸二酯酶4抑制剂类药物通过竞争性阻断磷酸二酯酶4对cAMP的降解作用,使T辅助细胞1(...
|
| 关 键 词： | 磷酸二酯酶4抑制剂 银屑病 环磷酸腺苷/蛋白激酶A通路 阿普司特 |
| 收稿时间： | 2022/1/10 0:00:00 |
Research progress on phosphodiesterase 4 inhibitors in treatment of psoriasis |
| |
| ZHANG Ting,ZHANG Min,LI Li,YAN Jing-ru,CHEN Pei-shan,HAO Yu-qin.Research progress on phosphodiesterase 4 inhibitors in treatment of psoriasis[J].Drugs & Clinic,2022,37(4):912-916. |
| |
| Authors: | ZHANG Ting ZHANG Min LI Li YAN Jing-ru CHEN Pei-shan HAO Yu-qin |
| |
| Institution: | Inner Mongolia Medical University, Hohehot 010000, China;Department of Dermatology, Baogang Hospital (the Third Affiliated Hospital of Inner Mongolia Medical University), Baotou 014010, China; Department of Dermatology, Peking University Third Hospital, Beijing 100191, China |
| |
| Abstract: | Psoriasis is an immune-mediated chronic inflammatory skin disease induced by a combination of genetics and the environment. cAMP/PKA pathway is closely related to the pathogenesis of psoriasis, and phosphodiesterase 4 is an enzyme that can specifically hydrolyze cAMP, so phosphodiesterase 4 becomes desired small molecule targets for psoriasis therapy. Phosphodiesterase 4 inhibitor drugs play a therapeutic role by competitively blocking the degradation of cAMP by phosphodiesterase 4, then weakening the immune response of Th1, Th2, and Th-17. Phosphodiesterase 4 inhibitor drugs, such as apremilast, roflumilast, criborrol, Hemay005, orlistat, MK-0873, tanimilast, and DRM02 have great potential in the treatment of psoriasis and its comorbidities. This article summarizes the mechanism of action, efficacy, and safety of phosphodiesterase 4 inhibitor drugs in treatment of psoriasis. |
| |
| Keywords: | phosphodiesterase 4 inhibitor psoriasis cAMP-PKA signaling pathway apremilast |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《现代药物与临床》浏览原始摘要信息 |
| 点击此处可从《现代药物与临床》下载免费的PDF全文 |
|
